BK Virus Infection Clinical Trial
Official title:
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
Every year, more than 25,000 patients worldwide receive lifesaving bone marrow transplantations with hematopoietic-cells from another person. It is estimated that over 75% of these patients will develop an infectious complication, of which approximately one third can be life-threatening. A significant proportion of these infections are caused by opportunistic viruses, such as BK virus. This virus establishes latent infection in most individuals, but does not normally cause disease. It can reactivate after hematopoietic-cell transplantation and represents the second most common viral infection in this patient population. BK virus is associated with kidney failure and a decreased chance of survival after hematopoietic-cell transplantation. There are no effective antiviral treatments for this disease. Despite being the second most common cause of clinical disease hematopoietic-cell transplantation, very little is known about this virus. To address this knowledge gap, the investigators aim to study patients with confirmed BK virus disease post allogeneic hematopoietic-cell transplantation. As part of this study, regular urine and blood tests will be done to understand how the virus behaves over time and which organs it affects. Blood and urine samples will also be obtained to study how the immune system rebuilds itself after hematopoietic-cell transplantation. Finally, an ultrasound of the kidneys and the bladder will be done to evaluate for any presence of disease in these organs. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02758288 -
BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
|
||
Completed |
NCT01624948 -
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Active, not recruiting |
NCT00684372 -
BK Viremia After Renal Transplantation
|
N/A | |
Recruiting |
NCT06219616 -
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
|
N/A | |
Not yet recruiting |
NCT05264259 -
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
|
||
Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Completed |
NCT04605484 -
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
|
Phase 2 | |
Terminated |
NCT04390113 -
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
|
Phase 3 | |
Withdrawn |
NCT02313844 -
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
|
Phase 1 | |
Recruiting |
NCT02479698 -
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
|
Phase 2 | |
Recruiting |
NCT05101213 -
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
|
Phase 1 | |
Completed |
NCT01789203 -
Ciprofloxacin for Prevention of BK Infection
|
Phase 4 | |
Completed |
NCT04693637 -
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Recruiting |
NCT05618275 -
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
|
||
Recruiting |
NCT04542733 -
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient
|
N/A | |
Recruiting |
NCT05042076 -
BK With VST for Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT04294472 -
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
|
Phase 2 |